sutacimig

all catalysts(0)

nothing on the calendar yet

News(2)

• After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
  With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
  fiercebiotech · 3d ago
• Two biotechs raise a combined $556M in latest spurt of IPOs
  Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.
  biopharma_dive · 3mo ago